Perrigo CEO Ousted Over Personal Conduct

Perrigo Chief Executive Patrick Lockwood-Taylor has resigned after the board found his personal conduct had violated company code.

WSJ • Jun 8, 2026

Perrigo Announces Leadership Transition

Albert A. Manzone Appointed Interim President and CEO Patrick Lockwood-Taylor Resigns as President and CEO and as a Member of the Board DUBLIN, June 8, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO) ("Perrigo" or the "Company"), a leading provider of Consumer Self-Care Products, today announced that its Board of Directors has appointed Albert A. Manzone, a member of the Company's Board, as Interim President and Chief Executive Officer, effective immediately.

PRNewsWire • Jun 8, 2026

Perrigo: This 11% Yielder Should Cut The Dividend

Perrigo is rated Hold due to a distressed balance sheet, high leverage, and unsustainable dividend coverage. PRGO's 10.9% dividend yield is not covered by free cash flow, with near-term risk of a dividend cut unless further divestitures occur. Recent asset sales, including the Dermacosmetics business, provide short-term relief but dilute margins and highlight the need for portfolio consolidation.

Seeking Alpha • Jun 6, 2026

Why Is Perrigo (PRGO) Down 9% Since Last Earnings Report?

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 5, 2026

Perrigo to Present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference

DUBLIN, May 26, 2026 /PRNewswire/ -- Perrigo Company plc (NYSE: PRGO), a leading global provider of consumer products, today announced that President and CEO Patrick Lockwood-Taylor and CFO Eduardo Bezerra are scheduled to present at the Oppenheimer 26th Annual Consumer Growth & E-Commerce Conference on Tuesday, June 9th at 10:30 AM EDT.  Interested parties can access the webcast on the Perrigo website at http://perrigo.investorroom.com/events-webcasts.

PRNewsWire • May 26, 2026

Perrigo Q1 Earnings Surpass Estimates, Sales Miss, Both Fall Y/Y

PRGO beats Q1 EPS estimates despite lower sales. Weakness in cough and cold demand offsets gains in Women's Health and Infant Formula.

Zacks Investment Research • May 7, 2026

Diamond Hill Small-Mid Cap Strategy Q1 2026 Portfolio Activity

We do not believe Humana's current share price reflects the company's earnings power, and as industry conditions normalize, we believe it can return to target margins over the long term. We initiated a position in Antero Resources, a natural gas exploration and production company, to gain exposure given our constructive long-term outlook for US natural gas. We exited our position in First Advantage, a leader in the background check space, to pursue other opportunities with less macro exposure and AI-disruption concerns.

Seeking Alpha • May 7, 2026

Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript

Perrigo Company plc (PRGO) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 6, 2026

Perrigo Reports First Quarter 2026 Financial Results From Continuing Operations

Mitigating category headwinds with market share gains through implementation of Three‑S plan. Specialty Care segment achieved net sales and segment operating income growth, led by continued momentum in Compeed ® , Opill ® , and ellaOne ® brands.

PRNewsWire • May 6, 2026

Perrigo (PRGO) Q1 Earnings Beat Estimates

Perrigo (PRGO) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.6 per share a year ago.

Zacks Investment Research • May 6, 2026